Danicopan
CAS: 1903768-17-1
Rif. 3D-DBD76817
1mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione |
Informazioni sul prodotto
- ACH-0144471
- DANICOPAN
- 2-Pyrrolidinecarboxamide, 1-[2-[3-acetyl-5-(2-methyl-5-pyrimidinyl)-1H-indazol-1-yl]acetyl]-N-(6-bromo-2-pyridinyl)-4-fluoro-, (2S,4R)-
- Danicopan
Danicopan is a monoclonal antibody that binds to the serine protease C5. It is used for the treatment of atypical hemolytic uremic syndrome (aHUS) and other autoimmune diseases. Danicopan inhibits the activation of the complement system by binding to C5, which prevents intravascular hemolysis. This drug also has a neutral pH and can be administered intravenously or subcutaneously. Danicopan has been shown to be effective in vitro and in vivo against aHUS, although its efficacy for other autoimmune diseases is not yet known.